Early Versus Deferred Treatment With Combined Fludarabine, Cyclophosphamide and Rituximab (FCR) Improves Event-Free Survival In Patients With High-Risk Binet Stage A Chronic Lymphocytic Leukemia – First Results Of a Randomized German-French Cooperative Phase III Trial
Schweighofer CD, Cymbalista F, Müller C, et al.
Key Points:
Benefit of FCR in CLL patients with early stage disease unclear
Survival outcomes of early versus deferred FCR therapy in treatment-naïve Binet stage A CLL patients with high risk disease reported
Treatment with FCR associated with significant event-free survival(EFS) advantage compared with wait and watch approach
No difference in OS
Implications:
- FCR may be considered treatment option in patients with early-stage high-risk CLL disease
View the original abstract on the ASH website.
